摘要
目的分析2型糖尿病采用二甲双胍以及瑞格列奈干预的作用。方法选择2019年8月—2020年8月该院收治的90例2型糖尿病患者为研究对象,随机将其分成常规1组(30例)、常规2组(30例)以及研究组(30例),予以常规1组患者二甲双胍用药,予以常规2组患者瑞格列奈用药,予以研究组患者二甲双胍以及瑞格列奈用药。对比用药前以及用药3个月后每组患者血糖指标、血脂指标、胰岛素指标水平;治疗总有效率;不良反应总出现率。结果用药3个月后研究组患者糖化血红蛋白、餐后2 h血糖、空腹血糖水平均低于常规1组、常规2组,差异有统计学意义(P<0.05)。用药3个月后研究组患者三酰甘油、总胆固醇水平均低于常规1组、常规2组,差异有统计学意义(P<0.05)。用药3个月后研究组患者胰岛素抵抗指数、空腹胰岛素、空腹C-肽水平均低于常规1组、常规2组,差异有统计学意义(P<0.05)。常规1组、常规2组、研究组患者治疗总有效率依次是73.33%、76.67%、96.67%,差异有统计学意义(P<0.05)。常规1组、常规2组、研究组患者不良反应总出现率分别是10.00%、6.66%、13.33%,差异无统计学意义(P>0.05)。结论2型糖尿病患者采用二甲双胍以及瑞格列奈进行治疗,能够改善血糖、血脂以及胰岛素水平,提升治疗效果,并且联合用药相较于单一用药不会显著增加药物不良反应,符合临床对用药安全性的需求。
Objective To analyze the effects of metformin and repaglinide intervention in type 2 diabetes. Methods 90 patients with type 2 diabetes admitted to the hospital were selected as the main body of the study from August2019 to August 2020. They were randomly divided into routine group 1(30 cases), routine group 2(30 cases) and study group(30 cases). Patients in routine group 1 were treated with metformin, and patients in routine group 2 were treated with repaglinide for experiments. Study group patients patients were treated with metformin and repaglinide.Compared the blood glucose, blood lipid and insulin levels of each group of patients before medication and three months after medication, as well as the total effective rate of treatment and the total incidence of adverse reactions.Results Three months after medication, the glycosylated hemoglobin, two-hour postprandial blood glucose, and fasting blood glucose levels of the study group were lower than those in the routine 1 and routine 2 groups,the difference was statistically significant(P<0.05). Three months after treatment, the levels of three usual glycerin and total cholesterol in the study group were lower than those in the conventional group 1 and the conventional group 2,the difference was statistically significant(P<0.05). Three months after the treatment, the insulin resistance index,fasting insulin, and fasting C-peptide levels of the study group were lower than those of the conventional group 1 and the conventional group 2,the difference was statistically significant(P<0.05). The total effective rate of treatment for patients in the routine 1, routine 2, and study groups were 73.33%, 76.67%, and 96.67%,the difference was statistically significant(P<0.05). The total incidence of adverse reactions in the routine 1, routine 2, and study groups were 10.00%, 6.66%, and 13.33%, respectively,the difference was not statistically significant(P>0.05). Conclusion The treatment of type 2 diabetic patients with metformin and repaglinide can improve blood glucose, blood lipids and insulin levels, and enhance the therapeutic effect. Compared with single medication, the combined medication will not significantly increase the adverse drug reactions, which is in line with the clinical safety of medication needs.
作者
肖淑玉
吴美珠
张乃广
刘全炯
XIAO Shuyu;WU Meizhu;ZHANG Naiguang;LIU Quanjiong(Department of Pharmacy,Datian General Hospital,Sanming,Fujian Province,366100 China;Department of Endocrinology,Datian General Hospital,Sanming,Fujian Province,366100 China)
出处
《糖尿病新世界》
2022年第1期90-94,共5页
Diabetes New World Magazine
关键词
二甲双胍
2型糖尿病
瑞格列奈
糖化血红蛋白
空腹血糖
Metformin
Type 2 diabetes
Repaglinide
Glycosylated hemoglobin
Fasting blood glucose
作者简介
肖淑玉(1977-),女,本科,副主任药师,主要从事基层医院药学工作。
